August 11, 2025
4 min watch
Key takeaways:
- Dyania Well being has developed an AI-based platform that automates affected person chart overview to prescreen sufferers for medical trials.
- Synapsis AI can monitor daily-changing medical information on the click on of a button.
One AI-powered well being care information firm is leveraging its proprietary giant language model-based platform to automate chart overview to prescreen potential candidates for medical trials and observational research.
Synapsis AI from Dyania Well being — based mostly in Jersey Metropolis, New Jersey — is working to match sufferers with advanced medical standards for medical trials, a activity that may be “nearly not possible” for a doctor and their workforce to perform provided that affected person traits can typically change each day, based on Eirini Schlosser, MSc, the corporate’s founder and CEO.
“What usually would take a human wherever from half-hour to 2 hours, our system can do longitudinally — let’s say again 20 years — and horizontally throughout a whole dataset, in about 0.3 seconds,” Schlosser instructed Healio. “We empower clinicians to have data at their fingertips a couple of affected person’s historical past with out having to learn all through. If a affected person had adversarial occasions to a selected drug they got 5 or 6 years in the past, we’re in a position to reply that with a fast click on of the button.”
Dyania Well being was one in every of simply 14 startups chosen for the 2025 CancerX Accelerator cohort, a bunch of revolutionary digital well being and AI startups centered on addressing crucial challenges in oncology. This system is hosted by Moffitt Most cancers Middle and launched in collaboration with the Workplace of the Nationwide Coordinator for Well being Data Know-how and the Workplace of the Assistant Secretary for Well being.
The CancerX Accelerator program offers collaborating startups with entry to trade champions, skilled mentors and a variety of help, from product suggestions and pilot alternatives to potential business agreements.
“Because the world begins to have the ability to undertake AI, I believe it’s essential to arm your self with data about how giant language fashions work, how AI programs work, how brokers work, in addition to what’s appropriately addressed with AI and what’s not,” Schlosser mentioned. “A powerful understanding of AI may be useful to be able to maximize one of the best look after sufferers and is admittedly what’s going to assist drugs be capable to make the most of the immense advantages AI can carry to well being care going ahead.”
On this video, Schlosser discusses how becoming a member of the CancerX Accelerator has fostered highly effective partnerships and alternatives for collaboration, in addition to opened the door to accelerating most cancers analysis.
Because the official media accomplice of the CancerX 2025 Accelerator cohort, Healio will showcase key breakthroughs and achievements by unique interviews with this yr’s startups in addition to alumni teams from the 2024 program.
Purposes for the 2026 CancerX Accelerator cohort will open Sept. 2, 2025, completely for CancerX members, with public purposes opening Sept. 9, 2025. Be a part of the CancerX group right here.
References:
For extra data:
Eirini Schlosser, MSc, may be reached on LinkedIn right here.
